Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837658 | 0.88 | MMP13 (0.69) | MMP13MMP14 | |
| SCHEMBL5836471 | 0.88 | MMP13 (0.71) | MMP13MMP14 | |
| SCHEMBL5836545 | 0.87 | MMP13 (0.73) | MMP13MMP14 | |
| SCHEMBL5836207 | 0.87 | MMP13 (0.72) | MMP13MMP14 | |
| SCHEMBL5836331 | 0.87 | MMP13 (0.77) | MMP13MMP14 | |
| SCHEMBL5835731 | 0.86 | MMP13 (1.00) | MMP13 | |
| SCHEMBL5836514 | 0.84 | MMP13 (0.77) | MMP13MMP14 | |
| SCHEMBL5835441 | 0.83 | MMP13 (0.74) | MMP13MMP14 | |
| SCHEMBL5836528 | 0.83 | MMP13 (0.71) | MMP13MMP14 | |
| SCHEMBL5836313 | 0.82 | MMP13 (0.67) | MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119201-B2 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1501515-B1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1501515-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER PRODUCTS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003090752-A1 | TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006057-A1 | Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP8, MMP9, MMP1 | MMP13 15/4885MMP14 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.